secwatch / observer

8-K filed December 20, 2024, 6:59 PM ET ticker RNAZ CIK 0001829635

other material confidence high sentiment positive materiality 0.65

TransCode opens Phase 1 Cohort 3; PK/PD from Cohort 1 show 66% miR-10b inhibition at 24h

Transcode Therapeutics, Inc.

Safety Review Committee approved third cohort after no significant safety/DLTs in Cohort 2.
Cohort 3 dose will be approximately double the Cohort 2 dose; enrollment ongoing.
Cohort 1 PK/PD data consistent with preclinical and Phase 0; 66% miR-10b inhibition at 24h post-infusion.
Plasma concentration of TTX-MC138 in humans exceeded nonclinical levels, suggesting favorable PK.
Several patients from Cohorts 1 and 2 remain on study for continued treatment.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-24-130812
form_type: 8-K
ticker: RNAZ
cik: 0001829635
company_name: Transcode Therapeutics, Inc.
filed_at: 2024-12-20T23:59:59+00:00
discovered_at: 2026-05-14T18:03:09.889784+00:00
generated_at: 2026-05-29T00:28:54.320823+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-24-130812
json_url: https://secwatch.observer/filing/0001104659-24-130812.json
markdown_url: https://secwatch.observer/filing/0001104659-24-130812.md
text_url: https://secwatch.observer/filing/0001104659-24-130812.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1829635/000110465924130812/0001104659-24-130812-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1829635/000110465924130812/tm2431511d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

KRMN

Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds

Karman Holdings Inc. June 1, 2026, 5:28 PM ET other_material Items 1.01, 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

GIPR

Generation Income Properties prices $5.0M public offering of 23.8M shares and warrants at $0.21/unit

GENERATION INCOME PROPERTIES, INC. June 1, 2026, 5:27 PM ET other_material Items 1.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

PECE

Peace Acquisition Corp closes IPO of 6M units at $10.00/unit, raising $60M

Peace Acquisition Corp. June 1, 2026, 5:16 PM ET other_material Items 3.02, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

MUX

McEwen receives $49.4M dividend from Minera Santa Cruz; total 2026 dividends now $58.2M

McEwen Inc. June 1, 2026, 5:14 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

MVIS

MicroVision seeks reverse stock split approval; ratio 1:5 to 1:15; annual meeting July 10, 2026

MICROVISION, INC. June 1, 2026, 5:02 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

VDTA

Vertical Data launches Vertical Edge, a direct-ownership edge data center platform

Vertical Data Inc. June 1, 2026, 4:47 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

XAIR

Beyond Air receives Nasdaq panel grant for continued listing; must meet bid price rule by July 31, 2026

Beyond Air, Inc. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CTOR

Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer

CITIUS ONCOLOGY, INC. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001104659-24-130812

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.